Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY26 results · Oct–Dec 2025
Sun Pharma Advanced Research Company reported revenue from operations of ₹8.45 crore (down 43.3% from Q3 FY25) and net loss of ₹80.42 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.45 | 14.91 | −43.3% | 7.86 | +7.5% |
| Other income | 0.00 | 0.19 | −100.0% | 0.01 | −100.0% |
| Total income | 8.45 | 15.10 | −44.0% | 7.87 | +7.4% |
| Profit before tax | (80.35) | (79.44) | Loss widened | (75.79) | Loss widened |
| Net profit for the period | (80.42) | (79.51) | Loss widened | (75.85) | Loss widened |
| EPS, basic (₹) | (2.48) | (2.45) | Loss widened | (2.34) | Loss widened |
| Net margin (%) | -951.7 | -533.3 | -965.0 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.45 | 14.91 | −43.3% | 7.86 | +7.5% |
| Other income | 0.00 | 0.19 | −100.0% | 0.01 | −100.0% |
| Total income | 8.45 | 15.10 | −44.0% | 7.87 | +7.4% |
| Profit before tax | (80.57) | (79.71) | Loss widened | (75.97) | Loss widened |
| Net profit for the period | (80.57) | (79.71) | Loss widened | (75.97) | Loss widened |
| EPS, basic (₹) | (2.48) | (2.46) | Loss widened | (2.34) | Loss widened |
| Net margin (%) | -953.5 | -534.6 | -966.5 |
Consolidated
- Filed with BSE
- 09 Feb 2026, 16:37 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2026, 16:37 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE